tradingkey.logo

Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals

ReutersMay 23, 2025 6:49 AM

- German drugmaker Bayer BAYGn.DE on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche's ROG.S rival treatment Vabysmo.

Bayer said in a statement the European Medicines Agency recommended that eye drug Eylea, at a high dose of 8 mg, can be injected at intervals of up to six months to treat wet age-related macular degeneration and diabetic macular oedema.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI